Neuromuscular disorders

Teams

Imagine's Offers

The database may not be exhaustive, please do not hesitate to contact us !

  • Amyotrophic lateral sclerosis (ALS)
    Genotype Phenotype
    Targets

    • In vivo models

      KO and KI zebrafish models for c9orf72, TDP-43, Fus, p62, TBK1

    • Protocols/Technics

      Phenotypic characterization and drug screening platform for zebrafish (live imaging, in vivo electrophysiology recordings, and drug screening on zebrafish models)

    • Specific targets

      c9orf72, TDP-43, Fus, p62, TBK1

    Therapeutics

    • Specific therapeutic approaches

      Innovative treatment (confidential)

    Clinical trials
    Spinal muscular atrophy
    Genotype Phenotype
    Targets

    • Protocols/Technics

      Phenotypic characterization and drug screening platform for zebrafish (live imaging, in vivo electrophysiology recordings, and drug screening on zebrafish models)

    • Specific targets

      SMN1 and SMN2

    Therapeutics
    Clinical trials

  • Muscular dystrophy

    Duchenne Muscular Dystrophy
    Genotype Phenotype

    • Cohorts

      Please, contact us

    Targets
    Therapeutics
    Clinical trials

Contacts

  • Thibaut Perchet

    Thibaut PERCHET

    Business development manager

    • thibaut.perchet@institutimagine.org
    • +33 1 42 75 42 55

Our founding members

Our campuses

Our labels